High-dose chemotherapy and autologous peripheral blood stem cell transplantation in the treatment of children and adolescents with Ewing sarcoma family of tumors.
10.3345/kjp.2013.56.9.401
- Author:
Juhee SEO
1
;
Dong Ho KIM
;
Jung Sub LIM
;
Jae Soo KOH
;
Ji Young YOO
;
Chang Bae KONG
;
Won Seok SONG
;
Wan Hyeong CHO
;
Dae Geun JEON
;
Soo Yong LEE
;
Jun Ah LEE
Author Information
1. Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea. junahlee@kcch.re.kr
- Publication Type:Original Article
- Keywords:
Ewing sarcoma;
High-dose chemotherapy;
Stem cell transplantation
- MeSH:
Adolescent;
Child;
Disease-Free Survival;
Humans;
Korea;
Male;
Neoplasm Metastasis;
Peripheral Blood Stem Cell Transplantation;
Pilot Projects;
Retrospective Studies;
Sarcoma, Ewing;
Stem Cell Transplantation;
Therapies, Investigational
- From:Korean Journal of Pediatrics
2013;56(9):401-406
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We performed a pilot study to determine the benefit of high-dose chemotherapy and autologous peripheral blood stem cell transplantation (HDCT/autoPBSCT) for patients with Ewing sarcoma family of tumors. METHODS: We retrospectively analyzed the data of patients who received HDCT/autoPBSCT at Korea Cancer Center Hospital. Patients with relapsed, metastatic, or centrally located tumors were eligible for the study. RESULTS: A total of 9 patients (3 male, 6 female), with a median age at HDCT/autoPBSCT of 13.4 years (range, 7.1 to 28.2 years), were included in this study. Patients underwent conventional chemotherapy and local control either by surgery or radiation therapy, and had achieved complete response (CR, n=7), partial response (n=1), or stable disease (n=1) prior to HDCT/autoPBSCT. There was no transplant-related mortality. However, the median duration of overall survival and event-free survival after HDCT/autoPBSCT were 13.3 months (range, 5.3 to 44.5 months) and 6.2 months (range, 2.1 to 44.5 months), respectively. At present, 4 patients are alive and 5 patients who experienced adverse events (2 metastasis, 2 local recur, and 1 progressive disease) survived for a median time of 2.8 months (range, 0.1 to 10.7 months). The 2-year survival after HDCT/autoPBSCT was 44.4%+/-16.6% and disease status at the time of HDCT/autoPBSCT tended to influence survival (57.1%+/-18.7% of cases with CR vs. 0% of cases with non-CR, P=0.07). CONCLUSION: Disease status at HDCT/autoPBSCT tended to influence survival. Further studies are necessary to define the role of HDCT/autoPBSCT and to identify subgroup of patients who might benefit from this investigational treatment.
